| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 06/13/2002 | WO2001098297A3 A thiazine oxazolidinone |
| 06/13/2002 | WO2001094415A3 Nuclear hormone receptor |
| 06/13/2002 | WO2001089533A3 Preparation for stabilizing the protective layer on the epithelium of the cornea or the alveoli |
| 06/13/2002 | WO2001070233A3 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof |
| 06/13/2002 | US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/13/2002 | US20020072630 Therapy |
| 06/13/2002 | US20020072538 NMDA NR2B antagonists for treatment |
| 06/13/2002 | US20020072529 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma |
| 06/13/2002 | US20020072526 Orally active salts with tyrosine kinase activity |
| 06/13/2002 | US20020072518 Bicyclic alphavbeta3 antagonists |
| 06/13/2002 | US20020072517 Substituted cyclic amine metalloprotease inhibitors |
| 06/13/2002 | US20020072500 3-(carboxy(hydroxy)alkylaminocarbonylmethylaminocarbonyl), 5-(tetrahydropyrimidin-2-yl-amino)phenol for example |
| 06/13/2002 | US20020072494 Angiogenesis inhibitor, K1-5 (protease-activated kringles 1-5) genetically engineered so it can be secreted from cells in which it is expressed; contains a secretory signal peptide and a pre-activation peptide derived from plasminogen |
| 06/13/2002 | US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia) |
| 06/13/2002 | US20020071874 Compositions containing therapeutically active components having enhanced solubility |
| 06/13/2002 | US20020071843 Targeted therapeutic agents |
| 06/13/2002 | US20020071837 Preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,OOO MW |
| 06/13/2002 | CA2678490A1 Isolated placental perfusate and placental cells isolated therefrom |
| 06/13/2002 | CA2436984A1 Urea substituted imidazoquinoline ethers |
| 06/13/2002 | CA2436983A1 Sulfonamido ether substituted imidazoquinolines |
| 06/13/2002 | CA2431203A1 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor |
| 06/13/2002 | CA2431151A1 Heterocyclic ether substituted imidazoquinolines |
| 06/13/2002 | CA2430989A1 Method of collecting placental stem cells |
| 06/13/2002 | CA2430966A1 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | CA2430844A1 Aryl ether substituted imidazoquinolines |
| 06/13/2002 | CA2430412A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors |
| 06/13/2002 | CA2429769A1 Methods of treatment involving human mda-7 |
| 06/13/2002 | CA2429728A1 Tyrosine kinase inhibitors |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/13/2002 | CA2428390A1 Enzymes |
| 06/12/2002 | EP1213289A1 N-benzenesulfonyl L-proline compounds as bradykinin antagonists |
| 06/12/2002 | EP1213018A1 Preventive and therapeutic agents for eye diseases |
| 06/12/2002 | EP1212433A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 06/12/2002 | EP1212417A2 Interleukin-1-receptor associated kinase-3 (irak3) |
| 06/12/2002 | EP1212344A1 B7-like polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212329A2 Amine derivatives of benzo[4,5]thieno[2,3-d]pyrimidine |
| 06/12/2002 | EP1212328A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 06/12/2002 | EP1212327A2 Pyrazolopyrimidines as therapeutic agents |
| 06/12/2002 | EP1212317A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 06/12/2002 | EP1212295A1 SUBSTITUTED $g(a)-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF |
| 06/12/2002 | EP1212077A2 Pharmaceutical composition of nateglinide and another antidiabetic agent |
| 06/12/2002 | EP1212071A1 Stable carotene-xanthophyll beadlet compositions and methods of use |
| 06/12/2002 | EP1212067A1 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 06/12/2002 | EP1212062A1 Use of thienopyrimidines |
| 06/12/2002 | EP1212058A1 Topical treatment for prevention of ocular infections |
| 06/12/2002 | EP1212054A2 Azetidine compounds in cns and eye diseases |
| 06/12/2002 | EP1212049A2 Use of thiamphenicol for thetreatment of chlamydia pneumoniae infections |
| 06/12/2002 | EP1028947B1 H3 receptor ligands of the phenyl-alkyl-imidazoles type |
| 06/12/2002 | EP1018884A4 METHOD OF TREATING BLINDNESS WITH hNT HUMAN NEURONAL CELLS |
| 06/12/2002 | EP0948357B1 Use of low molecular weight amino alcohols in ophthalmic compositions |
| 06/12/2002 | EP0888327B1 Benzopyran derivatives having leukotriene-antagonistic action |
| 06/12/2002 | EP0885204B1 Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds |
| 06/12/2002 | EP0873312B1 Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors |
| 06/12/2002 | EP0737200B1 Biologically active silicon compounds and their therapeutic and cosmetic applications |
| 06/12/2002 | EP0688211B1 Thalidomide for inhibition of angiogenesis |
| 06/12/2002 | EP0669833B1 Type ii tgf-beta-binding receptor fragment as therapeutic agent |
| 06/12/2002 | CN1353709A Bicyclic oxazolidinones as antibacterial agents |
| 06/12/2002 | CN1353701A Peptidyl heterocyclic ketones useful as tryptase inhibitors |
| 06/12/2002 | CN1353699A Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 06/12/2002 | CN1353697A 4-phenyl-pyrimidine derivatives |
| 06/12/2002 | CN1353694A Alpha-substituted carboxylic acid derivatives |
| 06/12/2002 | CN1353690A Bradykinin receptor antagonists |
| 06/12/2002 | CN1353608A Use of macrolide compounds for treatment of dry eye |
| 06/12/2002 | CN1353605A Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and use thereof |
| 06/12/2002 | CN1086138C Chinese patent medicine for curing myopia |
| 06/12/2002 | CN1086137C Chinese patent medicine for curing senile cataract |
| 06/11/2002 | US6403830 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 06/11/2002 | US6403791 Treatment of inflammatory diseases or autoimmune diseases in humans or animals |
| 06/11/2002 | US6403638 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
| 06/11/2002 | US6403609 Topical-use lubricant that gels when administered to the eye |
| 06/11/2002 | US6403598 Ophthalmic composition |
| 06/11/2002 | US6403590 Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
| 06/11/2002 | US6403087 Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of immunological disease |
| 06/11/2002 | CA2239705C Quinazoline-4-one ampa antagonists |
| 06/09/2002 | WO2002067993A1 Drug-releasing system of biodegradable polymer type |
| 06/06/2002 | WO2002044366A2 Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379 |
| 06/06/2002 | WO2002044183A2 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors |
| 06/06/2002 | WO2002044180A1 Lactam compounds and medicinal use thereof |
| 06/06/2002 | WO2002044165A1 Quinoline derivatives as nk-3 antagonists |
| 06/06/2002 | WO2002044158A1 Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents |
| 06/06/2002 | WO2002044154A1 Novel compounds |
| 06/06/2002 | WO2002044153A1 4-6-diphenyl pyridine derivatives as antiinflammatory agents |
| 06/06/2002 | WO2002044141A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 06/06/2002 | WO2002044126A2 Bisubstituted carbocyclic cyclophilin binding compounds and theirus |
| 06/06/2002 | WO2002044120A1 Compounds active at the glucocorticoid receptor iii |
| 06/06/2002 | WO2002043785A2 Intraocular implants for preventing transplant rejection in the eye |
| 06/06/2002 | WO2002043763A2 Combination of gaba agonists and aldose reductase inhibitors |
| 06/06/2002 | WO2002043762A2 Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| 06/06/2002 | WO2002043734A1 Novel compounds |
| 06/06/2002 | WO2002043722A2 Copper chelators for treating ocular inflammation |
| 06/06/2002 | WO2002043721A1 Treatment of statin side effects |
| 06/06/2002 | WO2002043664A2 Reducing cellular damage in the human body |
| 06/06/2002 | WO2002043648A2 Compounds active at the glucocorticoid receptor ii |
| 06/06/2002 | WO2002043578A2 Determination of risk and treatment of complications of prematurity |
| 06/06/2002 | WO2002020489A3 QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 06/06/2002 | WO2002013804A3 Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid |
| 06/06/2002 | WO2001094293A3 Benzamide ligands for the thyroid receptor |
| 06/06/2002 | WO2001090334A3 Drug metabolizing enzymes |
| 06/06/2002 | WO2001088116A9 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 06/06/2002 | WO2001079442A3 Albumin fusion proteins |